Literature DB >> 30453134

Updated European Consensus Statement on diagnosis and treatment of adult ADHD.

J J S Kooij1, D Bijlenga2, L Salerno3, R Jaeschke4, I Bitter5, J Balázs6, J Thome7, G Dom8, S Kasper9, C Nunes Filipe10, S Stes11, P Mohr12, S Leppämäki13, M Casas14, J Bobes15, J M Mccarthy16, V Richarte17, A Kjems Philipsen18, A Pehlivanidis19, A Niemela20, B Styr21, B Semerci22, B Bolea-Alamanac23, D Edvinsson24, D Baeyens25, D Wynchank2, E Sobanski26, A Philipsen27, F McNicholas28, H Caci29, I Mihailescu30, I Manor31, I Dobrescu32, T Saito33, J Krause34, J Fayyad35, J A Ramos-Quiroga14, K Foeken36, F Rad37, M Adamou38, M Ohlmeier39, M Fitzgerald40, M Gill41, M Lensing42, N Motavalli Mukaddes43, P Brudkiewicz44, P Gustafsson45, P Tani46, P Oswald47, P J Carpentier48, P De Rossi49, R Delorme50, S Markovska Simoska51, S Pallanti52, S Young53, S Bejerot54, T Lehtonen55, J Kustow56, U Müller-Sedgwick57, T Hirvikoski58, V Pironti59, Y Ginsberg60, Z Félegyházy61, M P Garcia-Portilla62, P Asherson63.   

Abstract

Background Attention-deficit/hyperactivity disorder (ADHD) is among the most common psychiatric disorders of childhood that often persists into adulthood and old age. Yet ADHD is currently underdiagnosed and undertreated in many European countries, leading to chronicity of symptoms and impairment, due to lack of, or ineffective treatment, and higher costs of illness. Methods The European Network Adult ADHD and the Section for Neurodevelopmental Disorders Across the Lifespan (NDAL) of the European Psychiatric Association (EPA), aim to increase awareness and knowledge of adult ADHD in and outside Europe. This Updated European Consensus Statement aims to support clinicians with research evidence and clinical experience from 63 experts of European and other countries in which ADHD in adults is recognized and treated. Results Besides reviewing the latest research on prevalence, persistence, genetics and neurobiology of ADHD, three major questions are addressed: (1) What is the clinical picture of ADHD in adults? (2) How should ADHD be properly diagnosed in adults? (3) How should adult ADHDbe effectively treated? Conclusions ADHD often presents as a lifelong impairing condition. The stigma surrounding ADHD, mainly due to lack of knowledge, increases the suffering of patients. Education on the lifespan perspective, diagnostic assessment, and treatment of ADHD must increase for students of general and mental health, and for psychiatry professionals. Instruments for screening and diagnosis of ADHD in adults are available, as are effective evidence-based treatments for ADHD and its negative outcomes. More research is needed on gender differences, and in older adults with ADHD.
Copyright © 2018 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Adult ADHD; Diagnosis; EPA; European Network Adult ADHD; Treatment; Updated European Consensus Statement

Mesh:

Substances:

Year:  2018        PMID: 30453134     DOI: 10.1016/j.eurpsy.2018.11.001

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  62 in total

1.  Attention deficit hyperactivity disorder in adults: common in primary care, misdiagnosed, and impairing, but highly responsive to treatment.

Authors:  Sally Cubbin; Laurence Leaver; Allyson Parry
Journal:  Br J Gen Pract       Date:  2020-08-27       Impact factor: 5.386

2.  Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensus.

Authors:  Susan Young; Jack Hollingdale; Michael Absoud; Patrick Bolton; Polly Branney; William Colley; Emily Craze; Mayuri Dave; Quinton Deeley; Emad Farrag; Gisli Gudjonsson; Peter Hill; Ho-Lan Liang; Clodagh Murphy; Peri Mackintosh; Marianna Murin; Fintan O'Regan; Dennis Ougrin; Patricia Rios; Nancy Stover; Eric Taylor; Emma Woodhouse
Journal:  BMC Med       Date:  2020-05-25       Impact factor: 8.775

3.  Investigative interviewing of youth with ADHD - recommendations for detective training.

Authors:  Kimberley J Cunial; Leanne M Casey; Clare Bell; Mark R Kebbell
Journal:  Psychiatr Psychol Law       Date:  2020-04-21

4.  The role of comorbid depressive symptoms on long-range temporal correlations in resting EEG in adults with ADHD.

Authors:  Matti Gärtner; Maria Strauß; Jue Huang; Eike Ahlers; Holger Bogatsch; Pierre Böhme; Thomas Ethofer; Andreas J Fallgatter; Jürgen Gallinat; Ulrich Hegerl; Isabella Heuser; Knut Hoffmann; Sarah Kittel-Schneider; Andreas Reif; Daniel Schöttle; Stefan Unterecker
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-07-04       Impact factor: 5.270

Review 5.  Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.

Authors:  Kim Boesen; Asger Sand Paludan-Müller; Peter C Gøtzsche; Karsten Juhl Jørgensen
Journal:  Cochrane Database Syst Rev       Date:  2022-02-24

6.  Gut microbiome and attention deficit/hyperactivity disorder: a systematic review.

Authors:  Dionysia Gkougka; Konstantinos Mitropoulos; Theodoros N Sergentanis; Artemis Tsitsika; Georgia Tzanakaki; Eleni Panagouli; Theodora Psaltopoulou; Loretta Thomaidis; Maria Tsolia
Journal:  Pediatr Res       Date:  2022-03-30       Impact factor: 3.756

7.  Prevalence and determinants of attention deficit/hyperactivity disorder (ADHD) medication use during pregnancy: Results from the Quebec Pregnancy/Children Cohort.

Authors:  Maxim Lemelin; Takoua Boukhris; Jin-Ping Zhao; Odile Sheehy; Anick Bérard
Journal:  Pharmacol Res Perspect       Date:  2021-05

8.  Non-credible symptom report in the clinical evaluation of adult ADHD: development and initial validation of a new validity index embedded in the Conners' adult ADHD rating scales.

Authors:  Miriam Becke; Lara Tucha; Matthias Weisbrod; Steffen Aschenbrenner; Oliver Tucha; Anselm B M Fuermaier
Journal:  J Neural Transm (Vienna)       Date:  2021-03-02       Impact factor: 3.850

9.  Efficacy of cognitive behavioural therapy in medicated adults with attention-deficit/hyperactivity disorder in multiple dimensions: a randomised controlled trial.

Authors:  Mei-Rong Pan; Shi-Yu Zhang; Sun-Wei Qiu; Lu Liu; Hai-Mei Li; Meng-Jie Zhao; Min Dong; Fei-Fei Si; Yu-Feng Wang; Qiu-Jin Qian
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-02-22       Impact factor: 5.270

10.  Dopamine adjusts the circadian gene expression of Per2 and Per3 in human dermal fibroblasts from ADHD patients.

Authors:  Frank Faltraco; Denise Palm; Adriana Uzoni; Lena Borchert; Frederick Simon; Oliver Tucha; Johannes Thome
Journal:  J Neural Transm (Vienna)       Date:  2021-07-18       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.